Particularly, PGE2 has been observed to promote osteoclastogenesis by inhibiting osteoprotegerin (OPG) production and stimulating receptor activator of the nuclear factor-kappa B (RANK) production, thus contributing to bone resorption that occurs during osteoporosis [56]. Here, TNFRSF11A is linked to osteoporosis.